$232 Million is the total value of DAFNA Capital Management LLC's 79 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 21.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| STXS | STEREOTAXIS INC | $26,677,000 | +80.4% | 13,680,554 | 0.0% | 11.51% | +56.5% | |
| SAGE | Buy | SAGE THERAPEUTICS INC | $19,691,000 | +97.1% | 123,806 | +18.7% | 8.50% | +71.0% |
| BPMC | Buy | BLUEPRINT MEDICINES CORP | $9,583,000 | +91.8% | 119,718 | +29.2% | 4.13% | +66.4% |
| ATRC | ATRICURE INC | $8,539,000 | -12.4% | 318,729 | 0.0% | 3.68% | -24.0% | |
| ALDR | Buy | ALDER BIOPHARMACEUTICALS INC | $7,794,000 | +92.0% | 571,013 | +44.2% | 3.36% | +66.6% |
| WVE | Buy | WAVE LIFE SCIENCES LTD | $7,403,000 | +267.6% | 190,554 | +297.8% | 3.19% | +218.8% |
| AERI | Buy | AERIE PHARMACEUTICALS INC | $7,209,000 | +40.9% | 151,770 | +7.1% | 3.11% | +22.2% |
| ZGNX | Sell | ZOGENIX INC | $7,138,000 | +36.2% | 129,764 | -9.7% | 3.08% | +18.1% |
| IBB | Sell | ISHARES TR NASDAQ BIOTECHetf | $6,865,000 | +9.7% | 61,400 | -5.4% | 2.96% | -4.8% |
| AKBA | AKEBIA THERAPEUTICS INC | $5,860,000 | +48.1% | 715,538 | 0.0% | 2.53% | +28.5% | |
| GLPG | Buy | GALAPAGOS NVspon adr | $5,843,000 | +53.1% | 49,609 | +19.2% | 2.52% | +32.8% |
| ASND | Sell | ASCENDIS PHARMA A Ssponsored adr | $5,224,000 | +8.0% | 44,380 | -42.5% | 2.25% | -6.3% |
| NBIX | NEUROCRINE BIOSCIENCES INC | $4,846,000 | +23.4% | 55,008 | 0.0% | 2.09% | +7.1% | |
| MNLO | Buy | MENLO THERAPEUTICS INC | $4,710,000 | +111.5% | 600,030 | +11.0% | 2.03% | +83.6% |
| ARGX | Sell | ARGENX SEsponsored adr | $4,451,000 | -20.5% | 35,650 | -38.9% | 1.92% | -31.1% |
| BLUE | BLUEBIRD BIO INC | $4,248,000 | +58.6% | 27,000 | 0.0% | 1.83% | +37.6% | |
| ARNA | ARENA PHARMACEUTICALS INC | $4,211,000 | +15.1% | 93,942 | 0.0% | 1.82% | -0.2% | |
| BHVN | BIOHAVEN PHARMACEUTICALS HOLD | $4,118,000 | +39.2% | 80,000 | 0.0% | 1.78% | +20.8% | |
| BCRX | Buy | BIOCRYST PHARMACEUTICALS INC | $4,057,000 | +8.2% | 498,415 | +7.3% | 1.75% | -6.1% |
| DXCM | Sell | DEXCOM INC | $3,851,000 | -5.5% | 32,338 | -4.9% | 1.66% | -18.0% |
| CBAY | Sell | CYMABAY THERAPEUTICS INC | $3,703,000 | +41.5% | 278,811 | -16.1% | 1.60% | +22.8% |
| PRQR | Sell | PROQR THERAPEUTICS N V | $3,627,000 | -15.7% | 261,521 | -4.0% | 1.56% | -26.8% |
| XENE | Buy | XENON PHARMACEUTICALS INC | $3,360,000 | +124.0% | 330,667 | +39.1% | 1.45% | +94.4% |
| RADIUS HEALTH INCnote 3.000% 9/0 | $3,336,000 | +8.9% | 4,000,000 | 0.0% | 1.44% | -5.6% | ||
| CYTK | Buy | CYTOKINETICS INC | $3,238,000 | +175.8% | 400,294 | +115.4% | 1.40% | +139.2% |
| LMNX | LUMINEX CORP | $3,184,000 | -0.4% | 138,391 | 0.0% | 1.37% | -13.6% | |
| FOMX | FOAMIX PHARMACEUTICALS LTD | $3,030,000 | +4.4% | 808,000 | 0.0% | 1.31% | -9.4% | |
| CARA | CARA THERAPEUTICS INC | $2,818,000 | +50.9% | 143,611 | 0.0% | 1.22% | +31.0% | |
| Sell | INTEC PHARMA LTD JERUSALEM | $2,799,000 | -19.9% | 381,789 | -17.6% | 1.21% | -30.5% | |
| BEAT | Sell | BIOTELEMETRY INC | $2,179,000 | -14.7% | 34,800 | -18.7% | 0.94% | -26.0% |
| CSII | Sell | CARDIOVASCULAR SYSTEMS INC | $2,173,000 | +15.2% | 56,200 | -15.1% | 0.94% | -0.1% |
| MRSN | New | MERSANA THERAPEUTICS INC | $2,121,000 | – | 403,300 | +100.0% | 0.92% | – |
| CRBP | Buy | CORBUS PHARMACEUTICALS HLDGS | $2,120,000 | +134.3% | 305,000 | +96.8% | 0.92% | +103.3% |
| KDMN | Buy | KADMON HOLDINGS INC | $1,999,000 | +1369.9% | 757,177 | +1056.0% | 0.86% | +1167.6% |
| NVRO | NEVRO CORP | $1,951,000 | +60.7% | 31,210 | 0.0% | 0.84% | +39.4% | |
| SCYX | SCYNEXIS INC | $1,922,000 | +213.5% | 1,272,927 | 0.0% | 0.83% | +171.8% | |
| ARDX | Buy | ARDELYX INC | $1,895,000 | +124.0% | 676,759 | +43.1% | 0.82% | +94.3% |
| ACHN | Sell | ACHILLION PHARMACEUTICALS | $1,839,000 | +83.5% | 621,182 | -1.4% | 0.79% | +59.2% |
| INSULET CORPnote 1.375% | $1,811,000 | +13.9% | 1,500,000 | 0.0% | 0.78% | -1.3% | ||
| DRNA | Buy | DICERNA PHARMACEUTICALS INC | $1,807,000 | +42.6% | 123,314 | +4.1% | 0.78% | +23.8% |
| ARQL | Sell | ARQULE INC | $1,787,000 | +40.9% | 373,164 | -18.5% | 0.77% | +22.2% |
| VKTX | VIKING THERAPEUTICS INC | $1,781,000 | +29.9% | 179,200 | 0.0% | 0.77% | +12.6% | |
| VBIV | VBI VACCINES INC | $1,590,000 | +16.9% | 850,000 | 0.0% | 0.69% | +1.5% | |
| AGTC | APPLIED GENETIC TECHNOL CORP | $1,505,000 | +68.3% | 359,190 | 0.0% | 0.65% | +45.8% | |
| JNJ | JOHNSON AND JOHNSON | $1,314,000 | +8.3% | 9,400 | 0.0% | 0.57% | -6.0% | |
| ADXS | New | ADVAXIS INC | $1,195,000 | – | 202,222 | +100.0% | 0.52% | – |
| GNCA | New | GENOCEA BIOSCIENCES INC | $1,174,000 | – | 1,989,653 | +100.0% | 0.51% | – |
| NTUS | Buy | NATUS MEDICAL INC | $1,089,000 | -15.6% | 42,900 | +13.2% | 0.47% | -26.7% |
| ASMB | ASSEMBLY BIOSCIENCES INC | $996,000 | -12.9% | 50,573 | 0.0% | 0.43% | -24.4% | |
| DERM | Buy | DERMIRA INC | $969,000 | +1245.8% | 71,500 | +615.0% | 0.42% | +1061.1% |
| INGN | New | INOGEN INC | $944,000 | – | 9,900 | +100.0% | 0.41% | – |
| ALEC | New | ALECTOR INC | $918,000 | – | 49,063 | +100.0% | 0.40% | – |
| ZFGN | Buy | ZAFGEN INC | $910,000 | +154.2% | 332,000 | +359.3% | 0.39% | +120.8% |
| MGNX | Sell | MACROGENICS INC | $899,000 | -9.6% | 50,000 | -36.1% | 0.39% | -21.5% |
| SPRO | SPERO THERAPEUTICS INC | $897,000 | +108.1% | 70,000 | 0.0% | 0.39% | +80.8% | |
| ABUS | ARBUTUS BIOPHARMA CORP | $884,000 | -6.6% | 246,900 | 0.0% | 0.38% | -18.9% | |
| RDUS | Buy | RADIUS HEALTH INC | $837,000 | +147.6% | 42,000 | +104.9% | 0.36% | +114.9% |
| MDGL | MADRIGAL PHARMACEUTICALS INC | $827,000 | +11.2% | 6,600 | 0.0% | 0.36% | -3.5% | |
| SVRA | New | SAVARA INC | $813,000 | – | 110,275 | +100.0% | 0.35% | – |
| PHAS | Sell | PHASEBIO PHARMACEUTICALS INC | $689,000 | +123.0% | 72,500 | -27.5% | 0.30% | +92.9% |
| KALV | Buy | KALVISTA PHARMACEUTICALS INC | $665,000 | +66.7% | 23,225 | +14.8% | 0.29% | +44.9% |
| KURA | Sell | KURA ONCOLOGY INC | $606,000 | -71.0% | 36,558 | -75.4% | 0.26% | -74.9% |
| CDTX | CIDARA THERAPEUTICS INC | $564,000 | +12.8% | 212,766 | 0.0% | 0.24% | -2.4% | |
| OBSV | Sell | OBSEVA SA | $555,000 | -1.1% | 43,408 | -2.1% | 0.24% | -14.3% |
| URGN | UROGEN PHARMA LTD | $554,000 | -14.2% | 15,000 | 0.0% | 0.24% | -25.5% | |
| ALDX | ALDEYRA THERAPEUTICS INC | $452,000 | +8.9% | 50,000 | 0.0% | 0.20% | -5.3% | |
| MASI | MASIMO CORPORATION | $415,000 | +28.9% | 3,000 | 0.0% | 0.18% | +11.9% | |
| STRO | SUTRO BIOPHARMA INC | $359,000 | +26.4% | 31,494 | 0.0% | 0.16% | +9.9% | |
| RIGL | RIGEL PHARMACEUTICALS INC | $354,000 | +12.0% | 137,600 | 0.0% | 0.15% | -2.5% | |
| DEXCOM INCnote 0.750% 5/1 | $336,000 | 0.0% | 250,000 | 0.0% | 0.14% | -13.2% | ||
| ARCT | Sell | ARCTURUS THERAPEUTICS LTD | $323,000 | -2.1% | 47,255 | -35.1% | 0.14% | -15.2% |
| NERV | Buy | MINERVA NEUROSCIENCES INC | $284,000 | +61.4% | 36,084 | +38.3% | 0.12% | +39.8% |
| ALDER BIOPHARMACEUTICALS INCnote 2.500% 2/0 | $240,000 | +19.4% | 250,000 | 0.0% | 0.10% | +4.0% | ||
| SLGL | SOL GEL TECHNOLOGIES LTD | $237,000 | +12.3% | 35,000 | 0.0% | 0.10% | -2.9% | |
| ALRN | New | AILERON THERAPEUTICS INC | $194,000 | – | 99,502 | +100.0% | 0.08% | – |
| BTX | Sell | BIOTIME INC | $124,000 | +36.3% | 95,000 | -5.0% | 0.05% | +17.8% |
| BLCM | BELLICUM PHARMACEUTICALS INC | $101,000 | +14.8% | 30,000 | 0.0% | 0.04% | 0.0% | |
| IMMU | Sell | IMMUNOMEDICS INC | $97,000 | -91.7% | 5,052 | -93.9% | 0.04% | -92.8% |
| ORMP | Buy | ORAMED PHARMACEUTICALS INC | $95,000 | +97.9% | 26,000 | +62.5% | 0.04% | +70.8% |
| NEOS | Exit | NEOS THERAPEUTICS INC | $0 | – | -27,500 | -100.0% | -0.02% | – |
| PTI | Exit | PROTEOSTASIS THERAPEUTICS INC | $0 | – | -54,569 | -100.0% | -0.09% | – |
| APTX | Exit | APTINYX INC | $0 | – | -14,500 | -100.0% | -0.12% | – |
| ADXS | Exit | ADVAXIS INC | $0 | – | -1,666,666 | -100.0% | -0.16% | – |
| LPTX | Exit | LEAP THERPEUTICS INC | $0 | – | -170,000 | -100.0% | -0.17% | – |
| VLRX | Exit | VALERITAS HOLDINGS INC | $0 | – | -1,325,000 | -100.0% | -0.21% | – |
| CNCE | Exit | CONCERT PHARMACEUTICALS INC | $0 | – | -105,656 | -100.0% | -0.66% | – |
| INCY | Exit | INCYTE CORP | $0 | – | -21,500 | -100.0% | -0.68% | – |
| TBIO | Exit | TRANSLATE BIO INC | $0 | – | -228,939 | -100.0% | -0.85% | – |
| NXTM | Exit | NXSTAGE MEDICAL INC | $0 | – | -312,119 | -100.0% | -4.44% | – |
| LOXO | Exit | LOXO ONCOLOGY INC | $0 | – | -181,675 | -100.0% | -12.65% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| STEREOTAXIS INC | 42 | Q3 2023 | 27.6% |
| ATRICURE INC | 42 | Q3 2023 | 11.4% |
| MASIMO CORPORATION | 42 | Q3 2023 | 1.8% |
| ASCENDIS PHARMA A S SPONSORED | 34 | Q3 2023 | 4.5% |
| AERIE PHARMACEUTICALS INC | 33 | Q3 2022 | 4.2% |
| GALAPAGOS NV-SPON ADR | 33 | Q3 2023 | 3.8% |
| XENON PHARMACEUTICALS INC | 33 | Q3 2023 | 3.6% |
| NEUROCRINE BIOSCIENCES INC | 32 | Q3 2023 | 2.9% |
| JOHNSON AND JOHNSON | 32 | Q1 2021 | 1.2% |
| ISHARES TR NASDQ BIOTECH | 30 | Q3 2023 | 4.0% |
View DAFNA Capital Management LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Stereotaxis, Inc. | March 08, 2018 | 13,680,554 | 23.4% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2018 | 983,000 | 2.9% |
| SUNESIS PHARMACEUTICALS INC | February 14, 2017 | 1,133,583 | 5.4% |
| WINDTREE THERAPEUTICS INC /DE/ | February 14, 2017 | 208,333 | 2.4% |
| ANAVEX LIFE SCIENCES CORP.Sold out | February 16, 2016 | 0 | 0.0% |
| DISCOVERY LABORATORIES INC /DE/ | February 16, 2016 | 10,658,699 | 9.2% |
| PRECISION OPTICS CORPORATION, INC. | February 13, 2015 | 311,537 | 5.0% |
| TearLab Corp | February 14, 2013 | 939,239 | 3.2% |
| VIKING SYSTEMS INC | February 14, 2012 | 3,781,468 | 5.2% |
View DAFNA Capital Management LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View DAFNA Capital Management LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.